Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Monday, February 3rd. Leerink ...

Investment analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for Owens & Minor in a report issued on Monday, February 3rd. Leerink Partnrs analyst M. Cherny now ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

The owner of the commercial shopping center next to the Lutherville light rail stop is pledging to continue to work to add ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price target of $18.00. The company’s shares ...

On Friday, Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant ...

Only in the crazy sector of metabolic medicines can 32% revenue growth be considered a disappointment. That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the ...

A minor uptick in Leerink Partners’ price target to $87 followed AstraZeneca’s strong third-quarter performance, with revenue reaching $13.565 billion – exceeding projections by 4%.

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

Leerink Partners served as exclusive financial advisor to Banner and Skadden, Arps, Slate, Meagher Flom LLP acted as legal advisor. To find out more about BAFIERTAM, please visit www.bafiertam.com.